3/11/2021

speaker
Operator
Conference Call Operator

webcast and conference call. Today's call is being recorded. At this time, I would like to turn the call over to Barbara Ryan, ELOX Investor Relations. Please begin.

speaker
Barbara Ryan
Investor Relations

Thank you, Victor. Welcome and thank you for joining us this afternoon for a review of ELOX Pharmaceutical's fourth quarter and full year 2020 financial results and business update. Joining me this afternoon are Dr. Greg Williams, our Chief Executive Officer, Neil Beloff, Chief Operating Officer and General Counsel, Dr. Tom Haverty, our Chief Medical Officer, Dr. Matthew Guderis, Vice President of Research, and Stephen McDonald, our Vice President of Finance and Accounting. Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the risk factors section in our most recent annual report on Form 10-K, filed with the Securities and Exchange Commission, as well as our other reports filed with the SEC. Any forward-looking statements represent our views as of today, March 11, 2021 only. A replay of this call will be available on the company's website, www.eloxpharma.com, following the call. It is now my great pleasure to turn the call over to Dr. Greg Williams, Chief Executive Officer of Elox Pharmaceuticals.

speaker
Dr. Greg Williams
Chief Executive Officer

Thank you, Barbara, and welcome to Elox's fourth quarter and full-year 2020 earnings webcast and conference call. We are continuing to advance our clinical and scientific programs for our ERSG library. Our highest priority is to complete our phase two clinical trials for ELXO2 in cystic fibrosis, and we are on track to report top line data in the first half of this year. We believe that these proof of concept data will be a substantial value inflection point for our company. As we previously shared, we are pleased that ELXO2 phase two clinical trials independent safety review committees have concluded several planned meetings and will have dose escalation up to the fourth and highest dose level. To date, no drug-related serious adverse events have been reported. We are conducting these global trials at top CF clinical trial sites and are grateful that the Cystic Fibrosis Foundation has recently expanded their financial support beyond the U.S. to provide increased funding for our global ELXO2 Phase II clinical trial program. The expressed level of interest and support from top investigators, trial sites, and patient advocacy groups has been a fantastic benefit to the program. Previously, we've shared that we continue to evaluate additional clinical trial sites in other countries where patient enrollment may be feasible. We are pleased to report that we are opening additional clinical trial sites in Australia and Canada. As you know, the Cystic Fibrosis Foundation has launched a $500 million Path to a Cure initiative aimed at finding cures for all CF patients. The foundation's initiative is prioritizing innovative approaches for individuals who do not respond to currently available treatments. This includes those with non-sense mutations, such as G542X, which is the focus of our ELXO2 Phase II clinical trials. Patients with nonsense-mediated cystic fibrosis represent about 12% of the CF population, according to the Cystic Fibrosis Foundation. The potential ability of an investigational drug, such as ELXO2, to restore functional CFTR protein production in these patients could be a major advance and substantially improve the length and quality of their lives. We believe that ELXO2 has the potential to be an important disease-modifying therapy for these patients who feel left behind and have few, if any, treatment options. We are committed to advancing the development of ELXO2 as quickly as possible. Substantial advances have been made in the treatment of patients with cystic fibrosis with the introduction of disease-modifying therapies, including the recent triple combination Trikafta from Vertex. While the benefits to patients have evolved as monotherapy transitions to combinations and most recently to the triple combo, there remains a high unmet medical need among the 12% of patients with nonsense mediated disease for whom there is no approved therapy. These difficult to treat patients are often the most severely afflicted by this disease. Patients with an F508 del allele are another difficult to treat population where a single agent Kalydeco was not effective. The next generation combination products, Orkambi and Syndeco, demonstrated a clinically important benefit in these patients. There was a 5 to 11 millimole per liter reduction in sweat chloride concentration for Orkambi and a reduction of 10 millimole per liter for Syndeco. These changes were associated with increases in FEV1 in the low to mid single digits. Trikafta, the triple combo therapy, has moved the needle even higher with sweat chloride concentration reductions from 42 to 45 millimole per liter, which were associated with 10 to 14% increases in FEV1. We're evaluating Elexo-2 as a single agent for another difficult-to-treat cystic fibrosis patient population, those with a G542X mutation on one or both alleles. Our CF Phase II program consists of two open-label trials, one for clinical investigators enrolling patients at sites in Europe, Israel, and Australia, the second enrolling patients in the United States and Canada. Both trials focus on CF patients with at least one G542X nonsense mutation. As I mentioned earlier, our global trials are being partially funded by the Cystic Fibrosis Foundation, and our protocol has been endorsed by the CFF Foundation the Therapeutic Development Network, the largest cystic fibrosis clinical trials network in the world. In Europe, our protocol has been endorsed by the ECFS Clinical Trial Network. The FDA has granted ELXO2 an orphan designation for cystic fibrosis, which confers certain important benefits to support development of medicines for underserved patient populations. ELXO2 has demonstrated pronounced CFTR read-through in plasmid, HBE, FRT, and transgenic mouse models. We've worked extensively with the hub, Hubrecht Organoid Technology, to better understand Elexo2's activity across the cystic fibrosis nonsense patient population in their library of patient-derived organoids. Elexo2 demonstrates significant restoration of CFTR activity in patient-derived organoids, representing over 75% of all nonsense alleles. Our screening programs continue to evaluate opportunities to advance ELXO2 and other novel molecules from our ERSG library for new indications. As our R&D team continues to advance these programs, we expect an acceleration in the pace of publishing our results in important scientific and medical journals. As a result of our progress, we've had six scientific manuscripts published since April 2020, and we expect the steady cadence of publications for ELXO2 and our ERSG library to continue. In January, the results of our renal impairment trial were published in the Journal of Clinical Pharmacology, and the results of our Phase 1b multiple ascending dose trial evaluating the safety and pharmacokinetics of ELXO2 in healthy subjects were published in the journal Clinical Pharmacology and Drug Development. In February, a scientific manuscript was published in the journal of cystic fibrosis on the results of our evaluation of ELXO2-mediated read-through using the CFTR-dependent forskolin-induced swelling assay across a selection of G542X homozygous and heterozygous patient-derived organoids. In October 2020, our senior medical consultant, Professor Ethan Karam, MD, a globally renowned cystic fibrosis expert, published a review of ELXO2 in the journal Expert Opinion on Investigational Drugs. We also had a scientific manuscript published in the Journal of Experimental Eye Research, which demonstrated the achievement of an important proof-of-concept milestone from our ongoing IND-enabling studies demonstrating restoration of protein production in the eye when injected intravitrally in a mouse model. In a few moments, Dr. Matt Goderis, our Vice President of Research, will provide you with some highlights from these most recent publications. We continue to be focused on delivering value to shareholders while fulfilling our mission to provide treatment options to patients with high unmet medical needs in the most safe and expeditious manner. We are the most advanced company tackling the great challenge of developing potential therapies for non-sense mutations and there's a high level of interest and enthusiasm in the scientific and clinical community for our programs as well as in the business community. We will continue to pursue partnerships where appropriate to expand our therapeutic footprint accelerate our progress, and advance our pipeline. We ended the fourth quarter of 2020 with $24.7 million in cash and cash equivalents, and we are on target to deliver top-line data for ELX02 in cystic fibrosis in the first half of this year. We have a strong and experienced team with expertise in clinical drug development, basic research, and regulatory affairs. I'm highly confident that we have the capabilities and the resources needed to deliver on our goals. I would now like to turn the call over to Dr. Matt Guderis, our Vice President of Research, who will expand on our recent publications and ongoing research activities.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API